Delveinsight

" Non-Small Cell Lung Cancer Pipeline Insight, 2020 " report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the  Non-Small Cell Lung Cancer  market. A detailed picture of the  Non-Small Cell Lung Cancer  pipeline landscape is provided, which includes the disease overview and  Non-Small Cell Lung Cancer  treatment guidelines. The assessment part of the report embraces in-depth  Non-Small Cell Lung Cancer  commercial assessment and clinical assessment of the  Non-Small Cell Lung Cancer  pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology,  Non-Small Cell Lung Cancer  collaborations, licensing, mergers and acquisition, fundi...

DelveInsight's ' Non-Small Cell Lung Cancer - Epidemiology Forecast to 2030 ' report delivers an in-depth understanding of the disease, historical and forecasted Non-Small Cell Lung Cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Key Highlights from report are: As per the DelveInsight analysis, the total incident cases of NSCLC in the 7MM were observed to be 484,726 cases in the year 2017. These cases are expected to grow with a significant CAGR in the study period 2017–2030. As per the DelveInsight estimates, the total incident cases of NSCLC patients by histology in the 7MM were observed to be 142,566, 228,106, 57,027, and 57,027 cases of squamous cell carcinoma, adenocarcinoma, large cell carcinoma, and others in the year 2017. The market size of NSCLC in the 7MM is expected to increase during study period. According to the estimates, the highest contribution in the market size of NSC...